Physician profile
Cher A Jacobsen
NPI 1427102938
$4,475.25
in general payments reported to CMS, 2019-2025
24 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,037 · 2020: $304 · 2021: $496 · 2022: $684 · 2023: $853 · 2024: $762 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,871 · Education: $83.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,871.39 |
| Education | $83.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $849.12 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $816.09 | 2020-2024 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $736.48 | 2019-2025 | Evenity, Repatha, Prolia |
| Janssen Pharmaceuticals, INC | $277.73 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $244.12 | 2019-2020 | |
| Abbott Laboratories | $237.88 | 2021-2024 | Freestyle Libre 3 |
| Pfizer INC. | $207.08 | 2019-2023 | |
| Lilly USA, LLC | $171.93 | 2023 | Mounjaro, Emgality, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.23 | 2023 | Trulance, Xifaxan |
| Ascendis Pharma Endocrinology INC | $144.53 | 2023-2025 | Yorvipath |
| Allergan, INC. | $122.15 | 2019 | |
| Mayne Pharma Commercial LLC | $90.42 | 2024-2025 | |
| Novo Nordisk INC | $84.10 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $60.42 | 2019 | |
| Axsome Therapeutics, INC. | $59.37 | 2024 | Auvelity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $53.46 | 2019 | |
| Sumitomo Pharma America, INC. | $50.90 | 2023-2024 | Gemtesa |
| Acadia Pharmaceuticals INC | $39.75 | 2025 | Daybue |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2023 | |
| Strongbridge US INC. | $15.80 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $14.77 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $14.00 | 2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $7.30 | 2025 | Voquezna |
| Janssen Biotech, INC. | $5.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cher Jacobsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.